The UK news has the story of a young Nigerian woman, Rose Akhalu, who is being targeted for deportation by the authorities because she has overstayed her student visa. The problem is that this woman has a functioning kidney transplant and deporting her to Nigeria might deny her access to immunosuppressive drugs. With dialysis such a scarce resource in Nigeria, sending her back and risking the viability of her kidney makes little sense. Without dialysis she would die. But, her chances of getting a dialysis slot apparently are slim.
The story raises serious ethical issues: “Rose's case raises several ethical questions. Is Britain responsible for the long term healthcare of foreign nationals and those on short stay visas? And if Rose is allowed to stay could this encourage so called 'health tourism' - immigrants and visitors who come to the UK expecting the NHS to pick up the bill for their healthcare.
The patient’s nephrologist has also weighed in: “Rose's kidney specialist Dr James Tattersall believes that sending her back would mean the "the kidney would not last very long". He says for Rose it would mean certain death.
That position is supported by the UK's National Kidney Federation. They have described Rose's situation as "cruel and unjust" and "a stressful position no transplant patient should find themselves in", adding "a journey leading to a mortal end is a frightening position for anyone to face, let alone one that could be easily averted."
Dr Tattersall also says if Rose's kidney is wasted, he believes the entire system of organ donation in the UK is endangered, because of a breakdown in trust. He says: "When a family gives permission for us to use an organ, they have to trust that we will use that kidney in the best possible way.”
The bottom-line is that it would be terrible for Rose Akhalu to be deported. Of course this should not be allowed to open the flood gates to abuse of a country’s largess. But there is a big difference between opening the flood gates and letting one or two people stay on compassionate grounds. What we really need is a global fund to support people like Rose Akhalu. The burden ought to be shared by all countries.
this is already health NHS tourism, transplant kidneys are rare enough without giving to foreign nationals
ReplyDeleteShe was by all accounts already in this country as a bona fide Ph.D student BEFORE her renal failure
DeletePretty good post, this is one of the best articles that I have ever seen !
ReplyDeleteuk based
Thanks for such a wonderful information I am looking forward to read your informative post.
ReplyDeleteresearch paper
The first theme is introduced in the membrane-bound receptors, including epidermal growth factor receptor (EGFR) family of receptors, from Spain, from the University Hospital Vall Desi Buren (Vall d'Hebron University Hospital) in Dr.Josep Tabernero be described. Since 75% to 90% of CRC patients can be observed in the expression of EGFR and EGFR are indicators of poor prognosis, researchers in the EGFR family of receptors for a lot of work, so that cetuximab and Panitumumab is approved for the treatment of CRC KRAS wild-type, both of which are the scope of the extracellular region of EGFR monoclonal antibodies. Such new trial including GA201, SYM004 studies (SYM004 can degrade and removal of cell surface receptors), as well as cetuximab and immunomodulatory drugs to that degree by the combination. It also discusses other membrane-bound receptors, including insulin-like growth (ILG) factor receptor, platelet-derived growth factor receptor (PDGFR), HCF c-Met receptor ligand and tumor necrosis factor-related apoptosis-inducing ligand body (TRAIL) receptors.
ReplyDeleteSimilarly, in the CRC research is promising scope intracellular signal transduction pathway components of the drug, this topic from the United States University of Colorado Dr.Wells Messersmith introduced. He discussed the ongoing development of promising new drugs, these drugs act on the MAPK, PI3K, SRC, Notch and hebgehog signal transduction pathway. Many drugs currently being carried out for various types of cancer in stage Ⅰ and Ⅱ early clinical trials. Expect these promising new approach in the near future for the clinician to bring more treatment options.
Finally, from the University of Texas Cancer Center Dr.Scott Kopetz MDAnderson introduced for the treatment of CRC angiogenesis inhibitors. To anti-vascular endothelial growth factor monoclonal antibody bevacizumab high success rate of the treatment begins, Dr.Kopetz recalled from the first generation and second generation angiogenesis inhibitors such as vatalanib and cediranib treatment failure of lessons learned, noting grasp early in the drug development process VEGF inhibitors pharmacokinetic importance "Unfortunately, there is no evidence that in addition to bevacizumab other than anti-angiogenic drugs can provide meaningful clinical benefit," Dr.Kopetz said he proposed a possible exception.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
BAY 61-3606 dihydrochloride
E-3810
BAY 61-3606
Cabozantinib S-malate
Pazopanib
Axitinib
OSI-930
Cediranib
MP470
Motesanib Diphosphate